What is Roth Capital’s Estimate for GANX Q1 Earnings?
Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) – Research analysts at Roth Capital issued their Q1 2026 earnings per share (EPS) estimates for shares of Gain Therapeutics in a research note issued to investors on Sunday, March 30th. Roth Capital analyst B. Pachaiyappan expects that the company will post earnings per share of ($0.27) for […]
Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) – Research analysts at Roth Capital issued their Q1 2026 earnings per share (EPS) estimates for shares of Gain Therapeutics in a research note issued to investors on Sunday, March 30th. Roth Capital analyst B. Pachaiyappan expects that the company will post earnings per share of ($0.27) for […]
